Microenvironmental Impact In The Treatment Of Acute Lymphoblastic Leukemia
Funder
National Health and Medical Research Council
Funding Amount
$621,458.00
Summary
Acute lymphoblastic leukemia remains one of the leading causes of death in children and outcomes for adults with this disease remain poor. This project examines how manipulation of the environment where leukemia arises can be used to therpaeutic advancage. Acute lymphoblastic leukemia cells are highly dependent on the support provided by bone marrow cells but the mechanisms are not well understood. Disrupting signals from the bone marrow cells has potential as a therapeutic strategy.
Strategies For Enhancing The Treatment Of Colon Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$590,785.00
Summary
Colorectal cancer is the third leading cause of cancer related death in Australia. Strategies to improve outcomes for these patients are urgently needed. This NHMRC SRF Fellowship will seek to identify new molecules in cancer cells which can be targeted to treat this disease, and to discover genes which can be used to improve patient response to treatment.
Prof. Simes will lead and develop research at the NHMRC Clinical Trials Centre in collaboration with major national and international cooperative groups. Research themes include integrating molecular science with trial design and embedding research routinely in health care. Projects include surgery for rectal cancer; novel targeted therapy in gastric cancer; aspirin to prevent colon cancer; placental transfusion for preterm babies; risk in heart disease; economic assessment of clinical trials.
Ovarian cancer is frequently fatal and an extremely distressing cause of death in women. Our research program draws on the Australian Ovarian Cancer Study (AOCS), involving over 2000 women with ovarian cancer to investigate the genetic causes, and molecular changes that control cancer growth and response to therapy. The program is part of Australia’s $27m commitment to the International Cancer Genomics Consortium, an ambitious, worldwide effort to map the cancer genome.
Targeting Mechanisms That Promote Cancer Cell Survival: Genetic And Chemical Approaches To Unravel The Molecular Mechanisms That Drive Tumour Formation, Develop Novel Molecular And Chemical Probes, And Discover New Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$751,854.00
Summary
One in three of us are likely to die from cancers. Groundbreaking research, including those made by Prof Huang, has revealed some of the reasons why cancers arise. An attractive way to transform the poor outcomes for cancer patients is to develop better medicines based on findings made by the basic researchers. Prof Huang leads a team at WEHI, including chemists, focused on developing better drugs that exploit knowledge garnered through such basic research in order to improve cancer treatment.
Translational Research Initiatives In Acute Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$631,010.00
Summary
Recent research has focussed on molecular characterisation of high-risk acute leukaemia subtypes. This proposal will combine the power of genomic analysis, global analysis of protein kinases and stringent preclinical drug testing in order to improve the treatment of these high-risk acute leukaemia subtypes. Several innovative and interrelated projects within this Program will utilise a unique and clinically relevant experimental model to achieve their goals.
Niche Regulation Of Normal And Malignant Stem Cells
Funder
National Health and Medical Research Council
Funding Amount
$622,655.00
Summary
Hematopoietic stem cells (HSC) reside in the bone marrow (BM) and make all the cells of the blood system. We study molecules in the BM regulating normal HSC to helping them survive chemotherapy. This means cancer patients should suffer less side-effects from their therapy. Some of these molecule also help leukaemia stem cells (LSC) resist chemotherapy. Inhibitors may a) reduce patient mortality caused by chemotherapy and b) sensitise LSC to chemotherapy enabling long-term cure.
Bone Growth For Healthy Development: Physiology, Pathophysiology, And Regeneration
Funder
National Health and Medical Research Council
Funding Amount
$621,458.00
Summary
Musculoskeletal damage is a major burden on individuals and our health care system. My research program will focus on improving bone health in three important areas: (1) children’s growth plate injury and growth defects; (2) bone loss and bone marrow defects from cancer chemotherapy; (3) ensuring that bone grows healthily in early life. The overall intent of this research is to develop new therapies when bone doesn’t grow well, or is damaged.
Immune Imprinting By Nanoparticles And Vaccines: New Principles And Translation Into The Clinic
Funder
National Health and Medical Research Council
Funding Amount
$631,010.00
Summary
Vaccines require adjuvants to be effective. Despite decades of research there is only one adjuvant approved for broad use in humans. Based on our prior findings I will engage new principles in nanotechnology, and deepen understanding of immune imprinting in various organs of the body including the lung, to develop 2nd generation broadly useful nanoadjuvants able to effectively treat cancer and malaria.